Prostatype Genomics AB (PROGEN) — Capital Reinvestment Ratio

Latest as of June 2020: 0.06x

Prostatype Genomics AB (PROGEN) has a Capital Reinvestment Ratio of 0.06x as of June 2020, meaning it reinvests 0% of its operating cash flow (Skr5.63 Million) in capital expenditures (Skr361.71K). Check how tangible is Prostatype Genomics AB's equity to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.06x
Capex / Operating Cash Flow

Operating Cash Flow

Skr5.63 Million
SEK

Capital Expenditures

Skr361.71K
SEK

Data as of

Jun 2020
Most recent filing

Annual Capital Reinvestment Ratio for Prostatype Genomics AB (None–None)

Year-by-year Capital Reinvestment Ratio for Prostatype Genomics AB from None to None. See PROGEN free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (SEK) Capital Expenditures YoY Change
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow